ASPIRE BIOPHARMA HOLDINGS IN (ASBP) Stock Income Statement
USA - NASDAQ:ASBP - US7389201077 - Common Stock
0.1057 USD
+0.01 (+15.77%)
0.1031 USD
0 (-2.46%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 16.42M | 3.09M | 1.34M | 980.00K | null | |||
| Research and Development | null | null | null | null | null | |||
| Selling, General, and Administrative Expenses | 15.80M | 3.09M | 1.34M | 980.00K | null | |||
| Operating Income | -16.42M | -3.09M | -1.34M | -980.00K | 0 | |||
| Interest Income/Expense | -1.95M | -342.90K | 5.80M | 4.32M | null | |||
| Other Income/Expense | null | -9.11M | null | null | null | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | -27.39M | -12.54M | 4.46M | 3.34M | null | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -27.39M | -12.54M | 4.46M | 3.34M | null | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.6816000000000002 | -1.5208 | 0.2328 | 0.11 | null | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in USD